News & Updates

Show Multimedia Only

Trabectedin flops against advanced ovarian, uterine carcinosarcoma

19 Oct 2022

Trabectedin falls short of meeting the prespecified antitumour activity criteria in patients with advanced ovarian (OC) or uterine carcinosarcoma (UC), according to the results of a phase II trial. However, there appears to be a modest clinical benefit in a group of heavily pretreated patients.

19 Oct 2022

SLN status delivers vital prognosis in stage IIB/C cutaneous melanoma

17 Oct 2022

The status of sentinel lymph nodes (SLN) can help predict the course of the disease in patients with clinical stage IIB/C cutaneous melanoma, suggests a study.

17 Oct 2022

Timely treatment of melanoma helps improve patient survival

16 Oct 2022

Delays in the treatment of melanoma may worsen overall (OM) and melanoma-specific mortality (MSM), suggest the results of a recent study.

16 Oct 2022

Does atezolizumab improve OS in patients with resected NSCLC and PD-L1 ≥1 percent?

16 Oct 2022 by

The first interim analysis of the phase III IMpower010 trial suggests an overall survival (OS) benefit with atezolizumab compared with best supportive care (BSC) in patients with resected non-small cell lung cancer (NSCLC) with PD-L1* tumour cell expression ≥1 percent.

16 Oct 2022

Sigmoidoscopy screening offers 15-year benefit in CRC incidence, mortality

15 Oct 2022

Sigmoidoscopy screening provides a significant and sustained effect on colorectal cancer (CRC) incidence and mortality for 15 years, according to a pooled analysis of randomized trials.

15 Oct 2022

Pemetrexed-based chemo boosts survival in NSCLC

15 Oct 2022

As an add-on to gefitinib monotherapy, pemetrexed-based chemotherapy improves survival outcomes in nonsmall cell lung cancer (NSCLC) patients harbouring EGFR mutations, a recent study has found.

15 Oct 2022

Lipid profile tied to outcomes in lung squamous cell carcinoma

15 Oct 2022

Among patients with lung squamous cell carcinoma (LUSC), lower levels of high-density lipoprotein cholesterol (HDL-C) appear to aggravate the risk of worse outcomes, a recent study has found.

15 Oct 2022

Adjuvant FOLFIRINOX ups survival in pancreatic cancer

15 Oct 2022 by

Adjuvant chemotherapy with a modified dose of FOLFIRINOX (mFOLFIRINOX) was associated with significantly better survival outcomes, particularly disease-free survival (DFS) and overall survival (OS), compared with single-agent gemcitabine in patients with resected pancreatic ductal adenocarcinoma (PDAC), according to a 5-year analysis of the PRODIGE 24/Canadian Cancer Trials Group PA6* study.

15 Oct 2022